BioCentury | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

...by 6.9%. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals Corp....
BioCentury | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

...the combination will be "explored preclinically" and both parties said there are no financial terms. RXi Pharmaceuticals Corp....
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Canbridge's U.S. office in Cambridge, Mass. He was CFO of Pfenex Inc. (NYSE-M:PFNX). RNAi company RXi Pharmaceuticals Corp....
BioCentury | Jul 5, 2017
Clinical News

RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

...year end. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals Corp....
BioCentury | May 26, 2017
Company News

PCI, RXi extend preclinical collaboration

...PCI Biotech Holding ASA (OSE:PCIB) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) extended a 2015 preclinical research collaboration and will...
...share IP that arises out of the deal. PCI Biotech Holding ASA (OSE:PCIB), Oslo, Norway RXi Pharmaceuticals Corp....
BioCentury | Jan 6, 2017
Finance

Good riddance

...$74.9 $1,068.9 $1,133.7 6% RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) 12/21/16 $24.4 $170.5 $174.0 2% RXi Pharmaceuticals Corp....
BioCentury | Dec 21, 2016
Financial News

RXi completes follow-on

...a share of preferred stock convertible into 1,111 shares of common stock and 1,111 warrants. RXi Pharmaceuticals Corp....
BioCentury | Nov 15, 2016
Financial News

RXi amends follow-on

...convertible preferred stock, which converts into 840 common shares, and warrants to purchase 420 shares. RXi Pharmaceuticals Corp....
BioCentury | Oct 31, 2016
Financial News

RXi Pharmaceuticals proposes follow-on

RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Business: Gene/Cell therapy, Dermatology, Ophthalmic Date announced: 2016-10-21 Type: Follow-on To be raised: Up to $20.7 million Units: TBD Price Prior: $1.19 Underwriter: Ladenburg Thalmann Note: Each class A...
BioCentury | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

...respond in time for publication (see BioCentury, May 4, 2015). MirImmune Inc. , Cambridge, Mass. RXi Pharmaceuticals Corp....
Items per page:
1 - 10 of 114
BioCentury | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

...by 6.9%. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals Corp....
BioCentury | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

...the combination will be "explored preclinically" and both parties said there are no financial terms. RXi Pharmaceuticals Corp....
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Canbridge's U.S. office in Cambridge, Mass. He was CFO of Pfenex Inc. (NYSE-M:PFNX). RNAi company RXi Pharmaceuticals Corp....
BioCentury | Jul 5, 2017
Clinical News

RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

...year end. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals Corp....
BioCentury | May 26, 2017
Company News

PCI, RXi extend preclinical collaboration

...PCI Biotech Holding ASA (OSE:PCIB) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) extended a 2015 preclinical research collaboration and will...
...share IP that arises out of the deal. PCI Biotech Holding ASA (OSE:PCIB), Oslo, Norway RXi Pharmaceuticals Corp....
BioCentury | Jan 6, 2017
Finance

Good riddance

...$74.9 $1,068.9 $1,133.7 6% RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) 12/21/16 $24.4 $170.5 $174.0 2% RXi Pharmaceuticals Corp....
BioCentury | Dec 21, 2016
Financial News

RXi completes follow-on

...a share of preferred stock convertible into 1,111 shares of common stock and 1,111 warrants. RXi Pharmaceuticals Corp....
BioCentury | Nov 15, 2016
Financial News

RXi amends follow-on

...convertible preferred stock, which converts into 840 common shares, and warrants to purchase 420 shares. RXi Pharmaceuticals Corp....
BioCentury | Oct 31, 2016
Financial News

RXi Pharmaceuticals proposes follow-on

RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Business: Gene/Cell therapy, Dermatology, Ophthalmic Date announced: 2016-10-21 Type: Follow-on To be raised: Up to $20.7 million Units: TBD Price Prior: $1.19 Underwriter: Ladenburg Thalmann Note: Each class A...
BioCentury | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

...respond in time for publication (see BioCentury, May 4, 2015). MirImmune Inc. , Cambridge, Mass. RXi Pharmaceuticals Corp....
Items per page:
1 - 10 of 114